By Terrie Johnson | UAB Community Health & Human Services Intern

Photo by Olia Danilevich on Pexels.com

The use of diabetes medication for weight loss is a growing trend among people facing obesity risks. A drug called semaglutide is used to help individuals manage their body mass. Based on existing studies, this medication is effective for weight loss. Its criticality is also based on limiting the development of type 2 diabetes (Singh et al., 2021). Patients receiving a dose of semaglutide medication have a higher chance of maintaining a desirable body mass index. Thus, the use of diabetes medications provides leverage for weight loss. This efficacy also makes it possible to mitigate the development and effects tied to type 2 diabetes. Therefore, the medication is a critical intervention for weight-related risk factors.

Even though diabetes medications such as semaglutide and liraglutide have positive effects on weight loss, they have negative implications. For example, their use curbs cravings for certain foods critical for relevant nutrients. The medications also lead to side effects like diarrhea and bloating (Singh et al., 2021). These issues may limit the achievement of the desired life quality. As such, there is a need to consider the reduction of side effects tied to diabetes medications. This stance would increase their efficacy in the advancement of weight loss. Thus, the interventions instigate the limitation of obesity-related issues that may reduce one’s quality of life.

Based on the review of existing studies, diabetes medication for weight loss is effective in mitigating weight-related issues. They also protect against the development of type 2 diabetes among at-risk populations (Singh et al., 2021). Thus, drugs, such as semaglutide, are instrumental to be applied in the weight loss process. They are effective in handling the risk of obesity and diabetes. Despite their side effects, the positive aspects are immense. Therefore, diabetes medication should be used to promote weight loss among at-risk patients.

Reference

Singh, G., Krauthamer, M., & Bjalme-Evans, M. (2021). Wegovy (semaglutide): A new weight loss drug for chronic weight management. Journal of Investigative Medicine, 70(1), 5–13. https://doi.org/10.1136/jim-2021-001952